Arthur McGivern, a partner in Goodwin Procter’sTechnology & Life Sciences Group, discusses how the number of U.S. companies debuting public stock continues to slow in recent years, as uncertainty over Brexit and other world events make investors nervous.
Read the full Bloomberg BNA article here.
Related Content
- Big Molecule WatchApril 18, 2024
Genentech and Dr. Reddy’s Settle BPCIA Rituximab Litigation
- Big Molecule WatchApril 17, 2024
MDL Panel Grants Transfer of Aflibercept BPCIA Case
- Big Molecule WatchApril 11, 2024
FDA Approves BMS and J&J CAR-T Cell Therapies for the Earlier Treatment of Multiple Myeloma
- Life Sciences PerspectivesApril 10, 2024
Janssen v. Teva: Not an April Fool’s Day Joke for Life Sciences Companies
- Big Molecule WatchApril 9, 2024
FDA Approves New Indication for AstraZeneca and Daiichi Sankyo’s Cancer Drug ENHERTU
- Life Sciences PerspectivesApril 1, 2024
A Look Ahead in Life Sciences: What We Are Tracking in Q2 2024 and Beyond
- InsightApril 1, 2024
A Look Ahead in Life Sciences: What We Are Tracking in Q2 2024 and Beyond
- Big Molecule WatchMarch 29, 2024
REGENXBIO and Sarepta Agree to Stay Litigation Pending Outcome of Sarepta’s IPR Petition
- Awards and RankingsApril 18, 2024
Goodwin is Number One in the Q1 2024 League Table Rankings
- Press ReleaseApril 18, 2024
Lumicell’s Novel Optical Imaging Agent Platform LUMISIGHT™ & Direct Visualization System for Detection of Residual Breast Cancer Receives FDA Approval
- Press ReleaseApril 17, 2024
Abingworth to Provide Teva with up to $150 Million in Financing to Advance Treatment of Asthma
- Press ReleaseApril 16, 2024
Goodwin Represents the Underwriters in PACS Group $450 Million IPO
- Press ReleaseApril 15, 2024
Goodwin Advises Exclusive Placement Agent in Acrivon Therapeutics’ $130 Million Private Placement
- Press ReleaseApril 10, 2024
Alpine Immune Sciences To Be Acquired by Vertex Pharmaceuticals For $4.9 Billion
- Press ReleaseApril 8, 2024
Premier Technology and Life Sciences Team Joins Goodwin in Boston
- Press ReleaseApril 3, 2024
AlmataBio Acquired by Avalo Therapeutics For $22.5 Million